Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mechanism of action and metabolic effects of exenatide in obesity

Next Previous
Trial Profile

Mechanism of action and metabolic effects of exenatide in obesity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics

Most Recent Events

  • 16 Sep 2016 Results assessing the effect of exenatide on glucose disposal, beta cell function and incretin hormones in non-diabetic obese subjects, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
  • 25 Jun 2013 Status changed from recruiting to completed, according to presentation of results at the 73rd Annual Scientific Sessions of the American Diabetes Association.
  • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top